Report Overview

China Hypophosphatasia Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hypophosphatasia (HPP) is a rare genetic disorder characterized by the abnormal development of bones and teeth. These abnormalities occur due to defective mineralization such as calcium and phosphorus. The global prevalence of Hypophosphatasia is approximately 1 in 100,000 live births. Hypophosphatasia disease is very harmful to patients of all ages, it is shown that children who showed the first symptoms of hypophosphatasia within 6 months of birth had a high mortality rate, and the mortality rate was 73% at 5 years of age.



Market Drivers

China is a growing market for hypophosphatasia due high demand for disease specific novel treatment, family history of hypophosphatasia, increase in global prevalence rate (1 in 100,000).

There are some restraining factors for growth of hypophosphatasia disease therapeutics market in China such as High cost and less treatment options available.